Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 180

Sort by

Sort Order Select

Journal Articles

Genomic Determinants of Response and Resistance to Pirtobrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia

Blood blood.2024027009.

https://doi.org/10.1182/blood.2024027009

Published: 2025

Includes: Supplemental data

Journal Articles

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN

Blood (2025) 146 (11): 1276–1285.

https://doi.org/10.1182/blood.2024024476

Published: 2025

Includes: Supplemental data

Journal Articles

International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations

Blood (2025) 146 (3): 291–303.

https://doi.org/10.1182/blood.2024028064

Published: 2025

Includes: Supplemental data

Journal Articles

Targeting WDR5/ATAD2 signaling by the CK2/IKAROS axis demonstrates therapeutic efficacy in T-ALL

Qi Han, Yan Gu, Huimin Xiang, Linyao Zhang, Yan Wang, Chan Yang, Jun Li, Chelsea Steiner, Rosa Lapalombella, Jennifer A. Woyach, Yiping Yang, Sinisa Dovat, Chunhua Song, Zheng Ge

Blood (2025) 145 (13): 1407–1421.

https://doi.org/10.1182/blood.2024024130

Published: 2025

Includes: Supplemental data

Journal Articles

Mutations in the Bruton Tyrosine Kinase ( BTK ) Gene in Patients with Chronic Lymphocytic Leukemia (CLL) Receiving BTK Inhibitors (BTKis)

Alan P Skarbnik, Alexey V. Danilov, Marc Hoffmann, Farrukh T. Awan, Frank Scarpa, Caryn Davies, Todd Oakland, Marina Kovach, Jenna Lilyquist, Veerendra Munugalavadla, Alan SM Yong, Vikram Shetty, John N. Allan, Jennifer A. Woyach

Blood (2024) 144 (Supplement 1): 4623.

https://doi.org/10.1182/blood-2024-209590

Published: 2024

Journal Articles

LP-168 (Rocbrutinib), a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase: Updates on the Phase 1 Trial and Initial Results of the CLL Gatekeeper Mutation Cohort

Jennifer A. Woyach, Danielle M. Brander, Boyu Hu, Kerry A. Rogers, Zulfa Omer, Deborah M. Stephens, Andrea Sitlinger, Fenlai Tan, Yi Chen, Stephen P. Anthony, Yu Chen, Kewei Shang, John C. Byrd

Blood (2024) 144 (Supplement 1): 4622.

https://doi.org/10.1182/blood-2024-205775

Published: 2024

Journal Articles

Outcomes of Patients with Chronic Lymphocytic Leukemia Discontinuing Bruton Tyrosine Kinase Inhibitors Due to Adverse Effects

Anthony G Mansour, Ying Huang, Aseel Alsouqi, Adam S Kittai, John C. Byrd, Michael R. Grever, Cecelia Miller, Gerard Lozanski, Mollie Moran, Margaret S. Lucas, Swetha Suresh, Cara Grantier, Corinne Hoffman, Mark Reid, Kerry A. Rogers, Seema A Bhat, Jennifer A. Woyach

Blood (2024) 144 (Supplement 1): 4629.

https://doi.org/10.1182/blood-2024-199676

Published: 2024

Journal Articles

Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel LP-168 (Rocbrutinib) Combinations Targeting BCL-2 Protein Members for Chronic Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 3587.

https://doi.org/10.1182/blood-2024-203522

Published: 2024

Journal Articles

CELESTIAL-TNCLL: An Ongoing, Open-Label, Multiregional, Phase 3 Study of Sonrotoclax (BGB-11417) + Zanubrutinib vs Venetoclax + Obinutuzumab for Treatment-Naive CLL

Piers E.M. Patten, Arnon P. Kater, Jennifer A. Woyach, Jianyong Li, Talha Munir, Tommi Salmi, Patrick Phuong, Tian Tian, Mazyar Shadman

Blood (2024) 144 (Supplement 1): 3257.1.

https://doi.org/10.1182/blood-2024-198737

Published: 2024

Journal Articles

BRAVE: A Phase 2 Trial Evaluating the Efficacy and Safety of Venetoclax in Combination with Bruton's Tyrosine Kinase Inhibitors in Patients with First-Line Chronic Lymphocytic Leukemia

Matthew S. Davids, John M. Burke, Jennifer A. Woyach, Mina Shahkarami, Katherine Eakle, Jinnie Ko, Vivek S. Chopra, Weize Huang, Rona Farighi, Richard H. Ko, Jeff P. Sharman, William G. Wierda

Blood (2024) 144 (Supplement 1): 3257.2.

https://doi.org/10.1182/blood-2024-201555

Published: 2024

Journal Articles

Prospective Randomized Phase 2 Study of Acalabrutinib + Obinutuzumab or Venetoclax in Previously Untreated CLL

Adam S Kittai, Ying Huang, Seema A Bhat, Michael R. Grever, Swetha Suresh, Gerard Lozanski, Mollie Moran, Megan Nussbaum, Jennifer A. Woyach, Kerry A. Rogers

Blood (2024) 144 (Supplement 1): 4634.1.

https://doi.org/10.1182/blood-2024-199561

Published: 2024

Journal Articles

Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy

Blood (2024) 144 (Supplement 1): 5099.

https://doi.org/10.1182/blood-2024-198742

Published: 2024

Journal Articles

Clinical Characteristics and Outcome in a Cohort of CLL Patients with BTK T474 Gatekeeper Mutation

Zulfa Omer, Max Yano, Jayesh Rai, Joyce Chen, Jennifer A. Woyach, Seema A. Bhat, Michael R. Grever, Dan Jones, Kerry A. Rogers, John C. Byrd

Blood (2024) 144 (Supplement 1): 1875.

https://doi.org/10.1182/blood-2024-209336

Published: 2024

Journal Articles

Protein Degrader WH25244 Eliminates Venetoclax Resistance Factors: Mutant or Hyperphosphorylated BCL2, and BCL-XL

Blood (2024) 144 (Supplement 1): 2786.

https://doi.org/10.1182/blood-2024-208159

Published: 2024

Journal Articles

Outcomes of Therapies Following Discontinuation of Non-Covalent Bruton's Tyrosine Kinase Inhibitors for Patients with Chronic Lymphocytic Leukemia and Richter Transformation: Results from an International, Multicenter Study

Blood (2024) 144 (Supplement 1): 1870.

https://doi.org/10.1182/blood-2024-194748

Published: 2024

Journal Articles

A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL

Blood (2024) 144 (Supplement 1): 3245.

https://doi.org/10.1182/blood-2024-205668

Published: 2024

Journal Articles

The Effects of an Online Curriculum Based Approach to CME on Hematologist/Oncologists' Ability to Treat Patients with BTK Inhibitors for Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Victoria Harvey-Jones, Sarah E. Bomba, Sanneke Koekkoek, Ahmad Sarris, Haleh Kadkhoda, Lauren Berger, Jennifer A. Woyach

Blood (2024) 144 (Supplement 1): 2446.

https://doi.org/10.1182/blood-2024-209529

Published: 2024

Journal Articles

Temporally Controlled MYC Overexpression in Chronic Lymphocytic Leukemia Accelerates Progression and Promotes Large B Cell Lymphoma Transformation

Ethan C. Whipp, Krithik Tella, Aidan Macaskill, Steven Sher, Casey Cempre, Jean Truxall, Mehdi Gharghabi, Fang Hao, Alexander R. Marr, Madeline Halpin, Pearlly S. Yan, Jennifer A. Woyach, Rosa Lapalombella

Blood (2024) 144 (Supplement 1): 2978.

https://doi.org/10.1182/blood-2024-210328

Published: 2024

Journal Articles

Topic Modeling of Genotyping of Transcriptomes Reveals Collaboration between BTK C481S -Mutant and Wild Type Cells in Btki-Resistant Chronic Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 4610.

https://doi.org/10.1182/blood-2024-205727

Published: 2024

Journal Articles

Targeting Inflammation in Tet2 Mutant Clonal Hematopoiesis Via Inhibition of Brd4 Demonstrates Activity in Both Murine and Human Models

Alexander R. Marr, Madeline Halpin, Dominique L. Corbin, Britten K. Gordon, Samon Benrashid, Ethan C. Whipp, Jean Truxall, Olivia Cahn, Bethany L. Mundy-Bosse, Julia Cooper, Marina Beltrami Moreira, James S. Blachly, Uma Borate, Jennifer A. Woyach, Rosa Lapalombella, Nicole R. Grieselhuber

Blood (2024) 144 (Supplement 1): 2661.

https://doi.org/10.1182/blood-2024-203526

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Genomic Determinants of Response and Resistance to Pirtobrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN

International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations

Targeting WDR5/ATAD2 signaling by the CK2/IKAROS axis demonstrates therapeutic efficacy in T-ALL

Mutations in the Bruton Tyrosine Kinase ( BTK ) Gene in Patients with Chronic Lymphocytic Leukemia (CLL) Receiving BTK Inhibitors (BTKis)

LP-168 (Rocbrutinib), a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase: Updates on the Phase 1 Trial and Initial Results of the CLL Gatekeeper Mutation Cohort

Outcomes of Patients with Chronic Lymphocytic Leukemia Discontinuing Bruton Tyrosine Kinase Inhibitors Due to Adverse Effects

Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel LP-168 (Rocbrutinib) Combinations Targeting BCL-2 Protein Members for Chronic Lymphocytic Leukemia

CELESTIAL-TNCLL: An Ongoing, Open-Label, Multiregional, Phase 3 Study of Sonrotoclax (BGB-11417) + Zanubrutinib vs Venetoclax + Obinutuzumab for Treatment-Naive CLL

BRAVE: A Phase 2 Trial Evaluating the Efficacy and Safety of Venetoclax in Combination with Bruton's Tyrosine Kinase Inhibitors in Patients with First-Line Chronic Lymphocytic Leukemia

Prospective Randomized Phase 2 Study of Acalabrutinib + Obinutuzumab or Venetoclax in Previously Untreated CLL

Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy

Clinical Characteristics and Outcome in a Cohort of CLL Patients with BTK T474 Gatekeeper Mutation

Protein Degrader WH25244 Eliminates Venetoclax Resistance Factors: Mutant or Hyperphosphorylated BCL2, and BCL-XL

Outcomes of Therapies Following Discontinuation of Non-Covalent Bruton's Tyrosine Kinase Inhibitors for Patients with Chronic Lymphocytic Leukemia and Richter Transformation: Results from an International, Multicenter Study

A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL

The Effects of an Online Curriculum Based Approach to CME on Hematologist/Oncologists' Ability to Treat Patients with BTK Inhibitors for Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Temporally Controlled MYC Overexpression in Chronic Lymphocytic Leukemia Accelerates Progression and Promotes Large B Cell Lymphoma Transformation

Topic Modeling of Genotyping of Transcriptomes Reveals Collaboration between BTK C481S -Mutant and Wild Type Cells in Btki-Resistant Chronic Lymphocytic Leukemia

Targeting Inflammation in Tet2 Mutant Clonal Hematopoiesis Via Inhibition of Brd4 Demonstrates Activity in Both Murine and Human Models

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only